Fathallah-Shaykh S, et al. - This phase 2, multicenter study was carried out to assess sevelamer carbonate (SC) as a management option for hyperphosphatemic pediatric patients with chronic kidney disease (CKD). In this patient population, sevelamer carbonate significantly lowered serum phosphorus levels without any serious safety concerns.